The rise in both global population and travel is contributing to the increase in spread of infectious diseases. Rapid and accurate identification of the infectious pathogens are imperative for timely intervention, better patient outcomes, and control and management of the spread of the infection. Conventional infectious disease diagnoses are performed in centralized labs; they have a long turnaround time and require expertise. Microfluidics-based infectious disease diagnostics, on the other hand, can enable multiplexed pathogen detection, rapid turnaround, and results at the point of care; they help healthcare providers take quick clinical decisions on treatment or isolation, and enable a lower rate of incidence.
In this report, the microfluidics-based infectious disease diagnostic innovations have been segmented by the property/phenomenon exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. It also covers growth drivers and the restraints in the micro-/nanofluidic infectious disease diagnostics industry, emerging microfluidic technologies, and companies to action.
GROWTH PIPELINE DIALOG™
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.